{
  "@type": "dcat:Dataset",
  "accessLevel": "public",
  "bureauCode": [
    "009:25"
  ],
  "contactPoint": {
    "@type": "vcard:Contact",
    "fn": "NIH/NCBI Data Team",
    "hasEmail": "mailto:info@ncbi.nlm.nih.gov"
  },
  "description": "The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are each independently hydrogen or C<SUB>1</SUB>-C<SUB>4 </SUB>alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.",
  "distribution": [
    {
      "@type": "dcat:Distribution",
      "description": "Access the complete Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES on the official website.",
      "downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400268-T1",
      "mediaType": "text/html",
      "title": "Official Data Source"
    }
  ],
  "identifier": "https://healthdata.gov/api/views/daks-4rnw",
  "issued": "2025-09-05",
  "keyword": [
    "chemistry",
    "innovation",
    "patent",
    "pubchem",
    "research"
  ],
  "landingPage": "https://healthdata.gov/d/daks-4rnw",
  "modified": "2025-09-06",
  "programCode": [
    "009:066"
  ],
  "publisher": {
    "@type": "org:Organization",
    "name": "National Center for Biotechnology Information (NCBI)"
  },
  "theme": [
    "NIH"
  ],
  "title": "Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES"
}